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Aims To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac
Outcomes Trial—2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA).
Methods
and results
The Blood Pressure Lowering Arm of the ASCOT trial (ASCOT-BPLA) compared two different antihypertensive
treatment strategies on cardiovascular outcomes. ASCOT-LLA was a double-blind placebo-controlled trial of
atorvastatin in those enrolled into ASCOT-BPLA with total cholesterol concentrations at baseline of 6.5 mmol/L.
A total of 19 342 hypertensive patients were enrolled in ASCOT-BPLA and 10 305 were further assigned either
atorvastatin, 10 mg, or placebo. ASCOT-LLA was stopped prematurely after a median 3.3 years follow-up because of
substantial cardiovascular benefits in those assigned atorvastatin. Trial physicians were invited to offer atorvastatin to
all ASCOT-LLA patients until the end of ASCOT-BPLA.
The primary outcome of ASCOT-LLA was combined fatal coronary heart disease (CHD) or non-fatal myocardial
infarction.
Secondaryoutcomes includedall coronaryevents,allcardiovasculareventsandprocedures, fatal andnon-fatal stroke,car-
diovascular mortality, all cause mortality, development of chronic stable angina, heart failure, and peripheral arterial disease.
By the end of ASCOT-LLA, there was a 36% relative risk reduction in primary events (n ¼ 254) in favour of
atorvastatin [hazard ratio (HR) 0.64, 95% CI: 0.50–0.83, P ¼ 0.0005]. At the end of ASCOT-BPLA, 2.2 years later, despite
extensive crossovers fromand to statin usage, the relative risk reduction in primaryevents (n ¼ 412) among those originally
assigned atorvastatin remained at 36% (HR 0.64, 95% CI: 0.53–0.78, P ¼ 0.0001). For almost all other endpoints, risk
reductions also remainedessentiallyunchangedand in thecaseof all causemortality, the risk reductionof15%nowachieved
borderline statistical significance (P ¼ 0.02).
Conclusion Carry-over benefits from those originally assigned atorvastatin but no longer taking the drug may account for
unchanged relative risk reductions in most cardiovascular endpoints observed 2 years after ASCOT-LLA closed.
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Introduction
In 2003, we reported the outcome of the lipid-lowering arm of the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA),1 a
placebo-controlled randomized trial of the effects of atorvastatin
10 mg daily in the primary prevention of coronary heart disease
(CHD) in hypertensive subjects who had a total cholesterol level
6.5 mmol/L. The trial was stopped prematurely after a median
3.3 years follow-up due to substantial benefits of atorvastatin on
the primary endpoint of non-fatal myocardial infarction and fatal
CHD, together with significant reductions in several other cardio-
vascular endpoints. ASCOT-LLA was part of a factorially designed
trial in which hypertensive patients with no prior history of CHD
were initially randomized to one of two antihypertensive treat-
ment strategies (a beta-blocker adding a thiazide diuretic as
required or a dihydropyridine calcium channel blocker (CCB),
adding an angiotensin converting enzyme inhibitor as required2,3
(ASCOT-BPLA).
After the termination of LLA, subjects continued in BPLA for a
further 2.2 years when the trial was stopped on the recommen-
dation of the Data Safety Monitoring Board (DSMB), owing to sub-
stantial mortality benefits in favour of the CCB-based treatment
strategy. The present report evaluates the cardiovascular out-
comes of those subjects originally assigned either atorvastatin or
placebo in the LLA and followed-up to the end of BPLA (5.5 years).
Methods
The detailed ASCOT protocol, including study design, organization,
clinical measurements, power calculations, recruitment rates, and base-
line characteristics has been published,2 and further detailed infor-
mation is available on the ASCOT website (www.ascotstudy.org). In
summary, the trial was an independent, investigator-led, multicentre
study with a prospective, randomized parallel group design incorporat-
ing by way of a 2  2 factorial approach, a comparison of two antihy-
pertensive treatment regimens and in a large subgroup, atorvastatin
with placebo. Patients eligible for inclusion into the LLA had to be eli-
gible for the blood pressure-lowering arm (BPLA) and have total choles-
terol concentrations of 6.5 mmol/L or less, and not currently taking a
statin or a fibrate. This population consisted of men and women aged
between 40 and 79 years at randomization, with either untreated hyper-
tension defined as systolic blood pressure of 160 mmHg or more, dias-
tolic blood pressure 100 mmHg or more, or both, or treated
hypertension with systolic blood pressure 140 mmHg or more, diastolic
blood pressure 90 mmHg or more, or both.
Trial participants were also required to have at least three of the fol-
lowing risk factors for cardiovascular disease: male sex, aged 55 years
or older, smoking, left ventricular hypertrophy, other specified
abnormalities on electrocardiogram, type II diabetes, peripheral arterial
disease, previous stroke or transient ischaemic attack, microalbumi-
nuria or proteinuria, ratio of plasma total cholesterol to
HDL-cholesterol concentration of 6 or higher or family history of pre-
mature CHD. Exclusion criteria included (among others): previous
myocardial infarction; currently treated angina; a cerebrovascular
event within the previous 3 months; fasting triglycerides 4.5 mmol/
L; heart failure; uncontrolled arrhythmias; or any clinically important
haematological or biochemical abnormality on routine screening.
The study conformed to good clinical practice guidelines4 and was
carried out in accordance with the Declaration of Helsinki.5 The
protocol and all subsequent amendments to the protocol were
reviewed and ratified by central and regional ethics review boards in
the UK and by national ethics and statutory bodies in Ireland and
the Nordic countries (Sweden, Denmark, Iceland, Norway, and
Finland).
Patients were recruited between February 1998 and May 2000. Eli-
gibility criteria were established and written informed consent was
obtained about 4 weeks before randomization. Blood pressure was
measured using standard procedures; non-fasting blood samples
were collected and 12-lead electrocardiograms were assessed cen-
trally. After the 4-week run-in period, eligible recruits were random-
ized, and they underwent a physical examination; blood pressure,
heart rate, and 12-lead electrocardiogram were again recorded.
Fasting blood samples were obtained for total cholesterol, HDL
cholesterol, triglyceride, and glucose levels.
Management of the BPLA is detailed elsewhere.2 Patients were ran-
domly assigned one of two antihypertensive regimens. Of the 19 342
patients randomized to one of the two antihypertensive regimens,
10 305 with a non-fasting cholesterol concentration 6.5 mmol/L at
the initial screening visit, who were untreated with a statin or fibrate
were further randomly assigned, by computer (using minimization pro-
cedures), to receive atorvastatin 10 mg daily or matching placebo.
Baseline characteristics of participants in these two randomized
groups were well matched and have previously been reported.1– 3 At
each follow-up visit, antihypertensive drug therapy was titrated to
achieve target blood pressures (,140/90 mmHg for non-diabetic
patients and ,130/80 mmHg for diabetic patients); information was
recorded about adverse events and any new cardiovascular events
or procedures, including the cause for any hospital admission. Infor-
mation on potential endpoints was reviewed by a blinded endpoint
committee.
Early closure of the
lipid-lowering arm
The DSMB decided a priori to use the symmetric Haybittle-Peto stat-
istical boundary (critical value Z ¼ 3) as a guideline for deciding to rec-
ommend early termination of the trial, which has the added advantage
that no material adjustment to the final P-values is required.6
On 2 September 2002, the DSMB recommended that the LLA of
the trial be stopped on the grounds that atorvastatin had resulted in
a highly significant reduction in the primary endpoint compared with
placebo and a significant reduction in the incidence of stroke.1
This recommendation was ratified by the Steering Committee,
whereupon all patients in LLA were recalled between October and
December 2002, for a final end-of-study visit. Trial physicians were
invited to offer atorvastatin 10 mg daily to all patients in LLA until
the end of BPLA, which was stopped between December 2004 and
June 2005 on the recommendation of the DSMB. Neither trial phys-
icians nor patients were aware of whether they had formerly been
assigned atorvastatin or placebo.
Statistical methods
We estimated that a total of at least 18 000 patients followed-up for an
average of 5 years were required in ASCOT-BPLA. Of these, we esti-
mated about 9,000 patients would be assigned atorvastatin 10 mg or
placebo. In LLA, we calculated power to be 90% (b ¼ 0.10) to
detect a relative effect of 30% on the primary endpoint of atorvastatin
10 mg compared with placebo. This calculation assumed a significance
level of 1% (a ¼ 0.01) and a yearly endpoint rate in the placebo group
of 13 per 1000 for 5 years of treatment. For the extension of 2.2 years
after ASCOT-LLA close-out and with 150 more primary endpoints,
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statistical power calculation showed that the study had 83% power
with a significance level of 5% for a reduction of 36% in hazard. We
compared the time to first primary endpoint event in the
atorvastatin and placebo groups on an intention-to-treat basis. All ana-
lyses excluded endpoints deemed invalid by the Endpoint Committee,
with statistical censoring enforced at the end of the study or at death.
Analysis of percentage time on statin was restricted to all those sub-
jects who had a date when the patient was last seen or known alive
in the study (disposition date), which fell 6 months after the lipid close-
out visit or later. Time on statin was calculated as the number of days
on statin between 6 months after the lipid close-out and the disposi-
tion date or 6 months after 1 October 2002 and the disposition
date for those with no lipid close-out visit.
The date used to indicate a silent myocardial infarction was taken as
the mean time between the dates of two electrocardiograms, the first
of which showed no myocardial infarction and the second of which did.
The intent to treat rule was strictly applied. Patients were analysed
according to their randomly allocated treatment group, regardless of
later treatment. Thus, a non-compliant patient belonged to the initial
randomized group. A patient who had switched drug was analysed
as if he/she belonged to the original randomized group. A patient
who was lost to follow-up is censored at the time of last visit.
For the main analyses, we used log-rank procedures and Cox’s pro-
portional hazards model to calculate confidence intervals.7 The pro-
portionality of hazard ratio (HR) by time was investigated by using
an interaction term of time and the indicator of treatment. No such
interactions in time or between periods were found for primary and
secondary endpoints. For tertiary endpoints, however, the HR
seemed to change in the extended period. Thus, for tertiary endpoints,
the HRs should be interpreted as mean estimates over the periods.
Cumulative incidence curves were generated by the Kaplan–Meier
method for all major endpoints in the active and placebo groups.
Results
The baseline characteristics of trial participants randomized to
either atorvastatin 10 mg or placebo were well matched
(Table 1). Participants were mainly white (95%) and male (81%),
with a mean age of 63 years. Baseline blood pressure and lipid sub-
fraction values were identical in the two groups.
LLA was stopped prematurely after 33 041 patient-years of
follow-up (median 3.3 years) when complete information was
obtained on 10 186 (98.8%) of the 10 305 patients originally ran-
domized. Of the remainder, vital status was obtained on all but
17 patients.
Following closure of LLA and by the end of BPLA, complete
information was available on 10 075 patients originally randomized
(Figure 1). However, between the closure of LLA and the sub-
sequent closure of BPLA there was substantial drop-in and
drop-out of statin therapy among those originally randomized to
placebo and atorvastatin, respectively. Consequently, at the
closure of BPLA, of those originally assigned atorvastatin, 63%
were still taking it, and of those originally assigned placebo, 56%
were taking atorvastatin (Table 2). A small percentage of additional
patients were receiving other statins (4 and 7%, respectively—
Table 2). In a further analysis estimating extensive statin use as
taking statins .90% of follow-up time, and minimal statin use as
,10% of follow-up time, of those originally assigned atorvastatin
50% continued to use statins extensively and 29% minimally. Of
those originally assigned placebo, the figures were 49 and 32%,
respectively.
Compared with placebo at the end of LLA (3.3 years), total
cholesterol and LDL-cholesterol concentrations among those allo-
cated were around 1.0 mmol/L lower than those allocated placebo
(Table 3, Figure 2A). However, by the end of BPLA, total and
LDL-cholesterol concentrations had lowered in those formerly
assigned placebo and had slightly increased in those formerly
assigned atorvastatin, such that these values were almost identical
in the two groups (Table 3, Figures 2A and B).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics
Atorvastatin,
n 5 5168
Placebo,
n5 5137
Demographics and clinical characteristics
Woman 979 (18.9%) 963 (18.7%)
Age (years)
60.0 1882 (36.4%) 1853 (36.1%)
.60.0 3286 (63.6%) 3284 (63.9%)
Mean (SD) 63.1 (8.5) 63.2 (8.6)
White 4889 (94.6%) 4863 (94.7%)
Current smoker 1718 (33.2%) 1656 (32.2%)
Alcohol consumption (unit/week) 8.0 (11.3) 8.2 (12.0)
Systolic blood pressure (mmHg) 164.2 (17.7) 164.2 (18.0)
Diastolic blood pressure (mmHg) 95.0 (10.3) 95.0 (10.3)
Heart rate (b.p.m.) 71.3 (12.8) 71.8 (12.6)
BMI (kg/m2) 28.6 (4.7) 28.7 (4.6)
Total cholesterol (mmol/L) 5.5 (0.8) 5.5 (0.8)
LDL cholesterol (mmol/L) 3.4 (0.7) 3.4 (0.7)
HDL cholesterol (mmol/L) 1.3 (0.4) 1.3 (0.4)
Triglycerides (mmol/L) 1.7 (0.9) 1.6 (0.9)
Glucose (mmol/L) 6.2 (2.1) 6.2 (2.1)
Creatinine (mmol/L) 99.0 (16.9) 99.0 (16.4)
Medical history
Previous stroke/transient
ischaemic attack (TIA)
485 (9.4%) 516 (10.0%)
Diabetesa 1370 (26.5%) 1370 (26.7%)
leftventricular hypertrophy (LVH)
(according to ECG or ECHO)a
1194 (23.1%) 1192 (23.2%)
ECG abnormalities other than
LVHa
1206 (23.3%) 1177 (22.9%)
Peripheral vascular disease 261 (5.1%) 253 (4.9%)
Other relevant cardiovascular
disease
188 (3.6%) 207 (4.0%)
Mean (SD) number of risk factors 3.7 (0.9) 3.7 (0.9)
Drug therapy
Previous antihypertensive
treatments
None 1021 (19.8%) 996 (19.4%)
1 2314 (44.8%) 2279 (44.4%)
2 1833 (35.5%) 1862 (36.2%)
Lipid-lowering therapy 41 (0.8%) 52 (1.0%)
Aspirin use 929 (18.0%) 902 (17.6%)
aIncludes information from investigator, ECG and glucose values.
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Concentrations of HDL cholesterol were similar in both groups
throughout the trial. Compared with placebo, atorvastatin reduced
triglycerides by about 0.2 mmol/L at the closure of LLA (Table 3,
Figure 2C), but by the end of BPLA, concentrations were almost
identical (Table 3, Figure 2D) in the two groups. Blood pressures
were similar throughout the trial in those assigned atorvastatin
and placebo and by the end of the trial had fallen to 137/78 in
both treatment groups.
At 3.3 years (the end of ASCOT- LLA), the primary endpoint
of non-fatal myocardial infarction and fatal CHD was significantly
lower by 35% (HR 0.65 [95% CI: 0.51–0.83], P ¼ 0.0006, in the
atorvastatin group compared with the placebo group. (Table 3,
Figure 3) Note that late reported endpoints which occurred
during LLA are now included. There is a highly significant
further divergence during the 2.2 years extension period for
the primary outcome despite lipid levels achieving similar valves
by the end of 5.5 years of follow-up. After 5.5 years, and with a
further 150 primary endpoints, the relative risk reduction of 36%
was unchanged (HR 0.64 95% CI: 0.53–0.78, P, 0.0001) (Table
4, Figure 3).
There were also significant reductions in a number of secondary
endpoints at the end of LLA which were sustained until the end of
BPLA, including total cardiovascular events and procedures (23% vs.
19%); total coronary events (29% vs. 27%), fatal and non-fatal stroke
(21% vs. 23%), and all cause mortality (13% vs. 15%), respectively
(Table 4 and Figures 3 and 4). Owing to the increase in the
number of deaths by the end of the extended period of observation,
the risk reduction in all cause mortality associated with assignment
to atorvastatin achieved borderline significance (P ¼ 0.02).
For the primary endpoint, cumulative event rates continued to
fall following the closure of LLA in both those originally assigned
atorvastatin and placebo. Similarly, event rates during the follow-up
from 3.3 to 5.5 years also fell in both groups of patients (Table 4).
The number of serious adverse events and rates of liver enzyme
abnormalities between those assigned atorvastatin or placebo did
not differ at any stage of the trial.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Total number of subjects and total per cent of subjects on atorvastatin and other statins respectively at lipid
close-out visit and final visit. All LLA subjects by atorvastatin and placebo subgroups
Atorvastatin, n 5 4978 Placebo, n 5 4916
Atorvastatin, n (%) Any statins, n (%) Atorvastatin, n (%) Any statins, n (%)
Lipid close-out visit 4113 (82.6%) 4167 (83.7%) 415 (8.4) 635 (12.9%)
Final visit 3122 (62.7%) 3322 (66.7%) 2752 (56.0%) 3089 (62.8%)
Figure 1 Trial profile
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Discussion
At the time of the early closure of LLA, it was considered appro-
priate in the light of the substantial benefits reported with atorvas-
tatin, to recommend to trial physicians that active therapy be
offered to all those included in ASCOT-LLA until the end of
BPLA. In the event, it was surprising, given the evidence base,
that there were physicians and/or patients who chose either not
to continue or not to start atorvastatin at the end of LLA. Thus,
by the end of BPLA 60% of the patients originally assigned
either placebo or atorvastatin were taking atorvastatin or other
statin. This is reflected by the equalization of total and
LDL-cholesterol concentrations by the end of the trial. Assuming
drop-in to statin therapy occurred at a constant rate throughout
the extended follow-up of just over 2 years, it can be predicted
that this should have accounted for a relative risk reduction in
primary event rates of around 19% in this group from the end of
LLA to the end of BPLA. This compared with the observed
reduction in this group from the end of the LLA to the end of
the BPLA of 15%. Estimates of this type are, however, problematic
and potentially confounded by accumulating benefits from
reductions in blood pressure. Further analyses taking account of
extensive or minimal use of any statins during follow-up, including
atorvastatin, do not alter these conclusions.
If there was no carry-over benefit from atorvastatin in those
stopping active treatment at the end of LLA, one might have
expected a modest rise in event rate in this group during the
final phase of the trial. In fact, event rates continued to decline
suggesting substantial and important carry-over benefits on cessa-
tion of active treatment.
If ASCOT-LLA had proceeded for 5.5 years with continuing
assignment to either atorvastatin or placebo, the risk reductions
in cardiovascular events associated with atorvastatin would have
been expected to continue at the same rates reported at the
end of LLA. The cardiovascular event rates reported between
the closures of LLA and BPLA were almost identical to those at
the termination of LLA, despite substantial changes to active
treatment rates after the closure of LLA among those originally
allocated to placebo and atorvastatin. Presumably, carry-over
benefits from statin among those who dropped out of therapy
and continuing benefits of those remaining on statins resulted in
similar relative risk benefits at the end of BPLA compared with
those at the conclusion of LLA. Also, attrition of susceptibles in
the placebo phase of the trial could contribute to reduced benefits
on cardiovascular event rates among new-statin users.
One effect of the early termination of LLA was that the study
had reduced power to evaluate the effect of atorvastatin on all
cause mortality. However, the extended follow-up presented
here involves a significantly increased number of deaths and
thereby power is restored such that the risk reduction associated
with atorvastatin now achieves borderline statistical significance for
a secondary endpoint.
Post-trial follow-up observations have been reported from the
double blind Scandinavian Simvastatin Survival Study (4S).8
During an extended 2 year follow-up after the termination of 4S,
about 80% of patients originally assigned placebo were given sim-
vastatin and there were fewer coronary and cardiovascular
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deaths in those originally assigned simvastatin, but differences in
event rates between those originally assigned statin and placebo
were less than those reported at the end of the double blind
trial. However, because of relatively small numbers of additional
deaths compared with those reported in the double blind trial,
overall HRs for coronary and cardiovascular deaths changed little
by the end of the extended follow-up (0.57 vs. 0.62 and 0.64 vs.
0.67, respectively). In a subsequent analysis of coronary and cardi-
ovascular deaths during a 5 year extension,9 the number of deaths
between those originally assigned simvastatin and placebo was very
similar, probably due to widespread statin use in both groups. The
benefits conferred by statin in those originally assigned placebo
presumably contributed to the reduction in relative risk between
statin and placebo for coronary and cardiovascular deaths
between the end of the double blind trial and the end of the
10 year follow-up (0.57 vs. 0.76 and 0.64 vs. 0.83, respectively).
In the Long-term Intervention with Pravastatin in Ischaemic
Disease (LIPID) study,10 patients with previous coronary disease
were randomly assigned pravastatin or placebo and were
followed-up for 6 years. Most (97%) had 2 years extended
follow-up during which 86% of those assigned placebo took open-
labelled pravastatin. During this period, patients originally assigned
pravastatin, although achieving cholesterol levels almost identical
with those originally assigned placebo continued to demonstrate
lower events rates for CHD deaths or non-fatal myocardial infarc-
tion (25%), stroke (24%), cardiovascular mortality (24%), and all
cause mortality (24%). These relative risk reductions during the
extended follow-up period are similar to those observed during
the double-blind randomized placebo controlled main trial.
A recent report of the 10-year post-trial follow-up of survivors
of the West of Scotland Coronary Prevention Study has demon-
strated that 5 years in trial treatment with pravastatin was associ-
ated with a significant reduction in coronary events for a
subsequent 10 years in men with hypercholesterolaemia who
had no history of myocardial infarction.11 Five years after the com-
pletion of the trial 37% of those formerly assigned placebo or
pravastatin were being treated with a statin, but there was no infor-
mation on the comparability of lipid levels at the end of the 10-year
follow-up. Nevertheless, it is reasonable to assume that they would
be similar in the two groups.
In a further study, ‘The Assessment of LEscol in Renal Transplan-
tation’, the ALERT trial, fluvastatin was compared with placebo in
renal transplant recipients. The primary composite endpoint of
cardiac death, non-fatal myocardial infarction and coronary
Figure 2 Lipid profiles over time throughout double blind and follow-up period for total cholesterol (A), LDL cholesterol (B), HDL choles-
terol (C ), and triglycerides (D)
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Table 4 Cardiovascular events during LLA trial (locked data), extension and followed to final visit, atorvastatin vs. placebo
LLAa LLA extension Followed to final visita
Atorvastatin Placebo Unadjusted
Hazard ratio
(95% CI)
P-value
Atorvastatin Placebo Unadjusted
Hazard ratio
(95% CI)
P-value
Atorvastatin Placebo Unadjusted
Hazard ratio
(95% CI)
P-valuen (%) Rateb n (%) Rateb n (%) Rateb n (%) Rateb n (%) Rateb n (%) Rateb
Primary endpoint
Non-fatal MI (incl
silent) þ fatal CHD
104 (2.0%) 6.3 158 (3.1%) 9.6 0.65 (0.51–0.83)
P ¼ 0.0006
59 (1.2%) 5.2 91 (1.9%) 8.3 0.63 (0.45–0.87)
P ¼ 0.0054
163 (3.2%) 5.8 249 (4.8%) 9.1 0.64 (0.53–0.78)
P ¼ ,.0001
Secondary endpoints
Total CV events
and procedures
410 (7.9%) 25.5 522 (10.2%) 32.9 0.77 (0.68–0.88)
P ¼ 0.0001
236 (5.1%) 22.4 262 (5.8%) 25.8 0.87 (0.73–1.03)
P ¼ 0.1093
646 (12.5%) 24.2 784 (15.3%) 30.1 0.81 (0.73–0.89)
P ¼ ,.0001
Total coronary
endpoint
194 (3.8%) 11.8 270 (5.3%) 16.6 0.71 (0.59–0.85)
P ¼ 0.0003
123 (2.5%) 11.1 154 (3.3%) 14.4 0.77 (0.61–0.98)
P ¼ 0.0334
317 (6.1%) 11.5 424 (8.3%) 15.7 0.73 (0.63–0.85)
P ¼ ,.0001
Non-fatal MI (excl
silent) þ fatal CHD
89 (1.7%) 5.4 141 (2.7%) 8.6 0.62 (0.48–0.81)
P ¼ 0.0005
55 (1.1%) 4.8 85 (1.8%) 7.7 0.63 (0.45–0.88)
P ¼ 0.0070
144 (2.8%) 5.1 226 (4.4%) 8.2 0.63 (0.51–0.77)
P ¼ ,.0001
All cause mortality 186 (3.6%) 11.1 212 (4.1%) 12.7 0.87 (0.72–1.06)
P ¼ 0.1798
201 (4.0%) 17.4 237 (4.8%) 20.9 0.83 (0.69–1.01)
P ¼ 0.0587
387 (7.5%) 13.7 449 (8.7%) 16.1 0.85 (0.74–0.98)
P ¼ 0.0219
Cardiovascular
mortality
75 (1.5%) 4.5 89 (1.7%) 5.4 0.84 (0.62–1.14)
P ¼ 0.2621
65 (1.3%) 5.6 76 (1.5%) 6.7 0.84 (0.60–1.17)
P ¼ 0.3048
140 (2.7%) 5.0 165 (3.2%) 5.9 0.84 (0.67–1.05)
P ¼ 0.1281
Fatal and non-fatal
stroke
110 (2.1%) 6.6 139 (2.7%) 8.5 0.79 (0.61–1.01)
P ¼ 0.0575
56 (1.1%) 5.0 73 (1.5%) 6.6 0.75 (0.53–1.06)
P ¼ 0.1047
166 (3.2%) 6.0 212 (4.1%) 7.7 0.77 (0.63–0.95)
P ¼ 0.0127
Fatal and non-fatal
heart failure
43 (0.8%) 2.6 43 (0.8%) 2.6 1.00 (0.65–1.52)
P ¼ 0.9902
33 (0.7%) 2.9 32 (0.7%) 2.8 1.01 (0.62–1.65)
P ¼ 0.9531
76 (1.5%) 2.7 75 (1.5%) 2.7 1.00 (0.73–1.38)
P ¼ 0.9809
Tertiary endpoints
Silent MI 15 (0.3%) 0.9 17 (0.3%) 1.0 0.88 (0.44–1.76)
P ¼ 0.7135
4 (0.1%) 0.3 7 (0.1%) 0.6 0.56 (0.16–1.91)
P ¼ 0.3487
19 (0.4%) 0.7 24 (0.5%) 0.9 0.78 (0.43–1.43)
P ¼ 0.4261
Unstable angina 22 (0.4%) 1.3 25 (0.5%) 1.5 0.88 (0.49–1.55)
P ¼ 0.6513
18 (0.4%) 1.6 11 (0.2%) 1.0 1.61 (0.76–3.41)
P ¼ 0.2088
40 (0.8%) 1.4 36 (0.7%) 1.3 1.10 (0.70–1.73)
P ¼ 0.6764
Chronic stable
angina
42 (0.8%) 2.5 70 (1.4%) 4.2 0.60 (0.41–0.87)
P ¼ 0.0072
28 (0.6%) 2.5 40 (0.8%) 3.6 0.68 (0.42–1.11)
P ¼ 0.1213
70 (1.4%) 2.5 110 (2.1%) 4.0 0.63 (0.46–0.85)
P ¼ 0.0021
Peripheral arterial
disease
49 (0.9%) 2.9 50 (1.0%) 3.0 0.98 (0.66–1.45)
P ¼ 0.9055
28 (0.6%) 2.5 32 (0.7%) 2.9 0.86 (0.52–1.43)
P ¼ 0.5562
77 (1.5%) 2.7 82 (1.6%) 3.0 0.93 (0.68–1.27)
p ¼ 0.6441
Life threatening
arrhythmias
10 (0.2%) 0.6 4 (0.1%) 0.2 2.48 (0.78–7.89)
P ¼ 0.1129
4 (0.1%) 0.3 7 (0.1%) 0.6 0.56 (0.16–1.92)
P ¼ 0.3503
14 (0.3%) 0.5 11 (0.2%) 0.4 1.26 (0.57–2.78)
P ¼ 0.5651
Develop. diabetes
mellitus
279 (7.3%) 23.6 251 (6.7%) 21.4 1.10 (0.93–1.31)
P ¼ 0.2524
84 (2.5%) 10.8 106 (3.2%) 14.0 0.78 (0.58–1.03)
P ¼ 0.0818
363 (9.6%) 18.5 357 (9.5%) 18.5 1.01 (0.87–1.16)
P ¼ 0.9428
Develop. renal
impairment
143 (2.8%) 8.7 135 (2.6%) 8.2 1.06 (0.84–1.34)
P ¼ 0.6463
95 (2.0%) 8.6 91 (1.9%) 8.3 1.03 (0.77–1.37)
P ¼ 0.8377
238 (4.6%) 8.6 226 (4.4%) 8.3 1.04 (0.87–1.25)
P ¼ 0.6392
aLate reported endpoints occurred during LLA are included as well.
bPer 1000 patient years.
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intervention procedures was non-significantly reduced by 17% at
the end of the formal follow-up period of 5.4 years.12 However,
despite widespread use of statins in those formerly assigned
placebo during an extended 2 year period of observation and
equalization of cholesterol levels, a significant risk reduction of
21% in the primary endpoint in those originally assigned fluvastatin
was observed.13 These observations on extended periods of
observation after several trials provide further convincing evidence
that withdrawal from active statin treatment is followed by sus-
tained treatment benefits in those with or without prior coronary
heart disease events. These observations indicate that the cost-
effectiveness of statins will be greater than that previously
estimated.14
Our findings during short-term extended follow-up of
ASCOT-LLA, albeit with substantial numbers of fatal and non-fatal
events reported, are similar to those of the 2-year extended
follow-up of the 4S trial8 and the LIPID trial.10 Although a
degree of protective carry-over effect afforded by statins, presum-
ably resulting from plaque stabilization, could reasonably be
expected over the short-term, it might be predicted that given suf-
ficient extended follow-up, assuming treatment rates equalize in
those originally assigned placebo and statin, that event rates
would converge, as witnessed in the longer term follow-up of 4S.
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